Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (5434)	2/12/1998 5:22:00 AM
From: James Baker	Read Replies (1) \| Respond to of 23519

Astra is an independent company. Janssen is the JNJ subsidiary which has the most recent agreement for Pacific Rim and other areas of distribution. From VIVUS website Press Release archives: VIVUS and Janssen Sign Second International Marketing Agreement Business Editors & Health/Medical Writers MENLO PARK, Calif.--(BW HealthWire)--Oct. 30, 1997--VIVUS, Inc. (NASDAQ:VVUS) today announced that the Company has signed an international marketing agreement with Janssen Pharmaceutica International, a subsidiary of Johnson & Johnson. This agreement for MUSE(R) (alprostadil), VIVUS' treatment for erectile dysfunction, amends the existing agreement with Janssen to include the Middle East, Russia, the Indian sub-continent, and Africa. VIVUS will receive a $2 million payment upon the execution of the agreement and additional payments will be made in the event that certain milestones are achieved. VIVUS will retain all proprietary rights to the product and will manufacture the product. Janssen will market, sell and distribute MUSE throughout the Middle East, Russia, the Indian sub-continent, and Africa, once the required regulatory approvals are obtained. The original marketing agreement with Janssen, signed in January of 1997, covered China, multiple Pacific Rim countries (excluding Japan), Canada, Mexico and South Africa. VIVUS and Janssen have established a joint development and marketing board, which will oversee all plans for development and commercialization of MUSE in these new markets. "Janssen has established a strong market presence in the regions covered under the new agreement," said Leland F. Wilson, President and Chief Executive Officer of VIVUS. "We look forward to working with Janssen to effectively reach these new markets for MUSE." MUSE was cleared for marketing by the U.S. Food and Drug Administration in November 1996 and was made commercially available in the U.S. in early January by VIVUS' direct sales force. VIVUS also has a marketing agreement with Astra AB of Sweden to market and sell MUSE throughout Europe, Australia, New Zealand, South America and Central America, once the required regulatory approvals are obtained.